



HA NOI CPC1 PHARMACEUTICAL
JOINT STOCK COMPANY

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No. 70 /2025/TB-CPC1HN

Ha Noi, March 31, 2025

PERIODIC INFORMATION DISCLOSURE

To: Hanoi Stock Exchange

According to Article 14, Clause 3 of Circular No. 96/2020/TT-BTC dated November 16, 2020 by the Ministry of Finance guiding the disclosure information disclosure on the stock market, CPC1 Hanoi Pharmaceutical Joint Stock Company of information the securities market, Ha Noi CPC1 Pharmaceutical Joint Stock Company is disclosing the 2024 financial report to the Hanoi Stock Exchange

1. Name of organization: Ha Noi CPC1 Pharmaceutical Joint Stock Company

Stock code: DTP

Address: Ha Binh Phuong Industrial Cluster, Van Binh Commune, Thuong Tin District, Hanoi city

Contact phone: 0243.3765503

Website: <https://cpc1hn.com.vn/>

2. Content of disclosure information:

Financial Report for 2024

☐ Separata Financial Statement (The listed company does not have any subsidiaries, and the superior accounting unit has dependent units);

☐ Consolidated Financial Statements (The listed company has subsidiaries);

☒ Consolidated Financial Statement (The listed company has dependent accounting units with separate accounting organizations)

- Cases requiring an explanation:

+ Corporate income tax profit at the financial result of the report changes by 10%

or more compared to the same period of the previous year:

☐ Yes

☒ No

Explanation document if marks "Yes":

☐ Yes

☐ No



94 - C.T.C.P
Y
IN
HẨM
NỘI
- TP. HÀ NỘI

FINANCIAL STATEMENTS

HANOI CPCI PHARMACEUTICAL JOINT STOCK COMPANY

For the fiscal year ended as at 31 December 2024

(Audited)

CONTENTS

	Page
Report of the Board of Management	02 - 03
Independent Auditors' Report	04 - 05
Audited Financial Statements	06 - 39
- Statement of Financial position	06 - 07
- Statement of Income	08
- Statement of Cash flows	09
- Notes to the Financial Statements	10 - 39

REPORT OF THE BOARD OF MANAGEMENT

The Board of Management of Hanoi CPC1 Pharmaceutical Joint Stock Company (“the Company”) presents its report and the Company’s Financial Statements for the fiscal year ended as at 31 December 2024.

THE COMPANY

CPC1 Hanoi Pharmaceutical Joint Stock Company was established and operated under the Certificate of Business Registration of Joint Stock Company No. 0103039694 issued by the Hanoi Department of Planning and Investment for the first time on 5 August 2009, registered for the 16th change on 23 March 2023.

The Company’s head office is located at: Ha Binh Phuong Industrial Cluster, Van Binh Commune, Thuong Tin District, Hanoi.

BOARD OF DIRECTORS, BOARD OF MANAGEMENT AND BOARD OF SUPERVISION

Members of the Board of Directors during the fiscal year and to the reporting date are:

Mr. Le Nam Thang	Chairman	(Re-appointed on 05/04/2024)
Mr. Nguyen Doan Liem	Member	(Re-appointed on 05/04/2024)
Mr. Nguyen Thanh Binh	Member	(Re-appointed on 05/04/2024)
Mr. Tran Nghia Loi	Member	(Appointed on 05/04/2024)
Mr. Vu Van Ha	Member	(Term 2020-2024 ends on 05/04/2024)

Members of the Board of Management in the fiscal year and to the reporting date are:

Mr. Nguyen Thanh Binh	General Director
Mr. Tran Minh Thanh	Vice General Director
Mr. Le Nam Thang	Vice General Director

Members of the Board of Supervision are:

Mrs. Tran Thuy Khanh	Head of Board	(Re-appointed on 05/04/2024)
Mrs. Ha Thi Mai	Member	(Appointed on 05/04/2024)
Mrs. Nguyen Thi Kim Oanh	Member	(Appointed on 05/04/2024)
Mrs. Tran Thi Phuong Thao	Member	(Term 2020-2024 ends on 05/04/2024)
Mrs. Truong Thi Hue	Member	(Term 2020-2024 ends on 05/04/2024)

LEGAL REPRESENTATIVE

The legal representative of the Company during the year and until the preparation of this Financial Statement is Mr. Le Nam Thang – Chairman of the Board of Directors.

AUDITORS

The auditors of AASC Auditing Firm Company Limited have taken the audit of Financial Statements for the Company.

STATEMENT OF THE BOARD OF MANAGEMENT'S RESPONSIBILITY IN RESPECT OF THE FINANCIAL STATEMENTS

The Board of Management is responsible for the Financial Statements which give a true and fair view of the financial position of the Company, its operating results and its cash flows for the year. In preparing those Financial Statements, the Board of Management is required to:

- Establish and maintain of an internal control system which is determined necessary by the Board of Directors and Board of Management to ensure the preparation and presentation of Financial Statements do not contain any material misstatement caused by errors or frauds;
- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the Financial Statements;
- Prepare the Financial Statements on the basis of compliance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of Financial Statements;
- Prepare the Financial Statements on going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Board of Management is responsible for ensuring that accounting records are kept to reflect the financial position of the Company, with reasonable accuracy at any time and to ensure that the Financial Statements comply with the current State's regulations. It is responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Board of Management, confirms that the Financial Statements give a true and fair view of the financial position at 31 December 2024, its operation results and cash flows for the fiscal year ended as at 31 December 2024 of Company in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of Financial Statements.

Other commitments

The Board of Directors commits that the Company complies with Decree 155/2020/ND-CP dated 31/12/2020 detailing the implementation of a number of articles of the Securities Law and the Company does not violate the obligation to disclose information as prescribed in Circular No. 96/2020/TT-BTC dated 16/11/2020 of the Ministry of Finance guiding information disclosure on the Securities Market and Circular No. 68/2024/TT-BTC dated 18/09/2024 of the Ministry of Finance on amendments and supplements to a number of articles of Circular No. 96/2020/TT-BTC.

On behalf of the Board of Management,



Le Nam Thang
Chairman of the Board of Directors
Hanoi, 29 March 2025

No: 290325.011/BCTC.KT3

INDEPENDENT AUDITORS' REPORT

**To: Shareholders, the Board of Directors and Board of Management
Hanoi CPC1 Pharmaceutical Joint Stock Company**

We have audited the Financial Statements of Hanoi CPC1 Pharmaceutical Joint Stock Company prepared on 29 March 2025, as set out on pages 06 to 39, including: Statement of Financial position as at 31 December 2024, Statement of Income, Statement of Cash flows and Notes to the Financial Statements for the fiscal year ended as at 31 December 2024.

Board of Management's responsibility

The Board of Management is responsible for the preparation and presentation of Financial Statements that give a true and fair view in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of financial statements and for such internal control as management determines is necessary to enable the preparation and presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these Financial Statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. Those standards require that we comply with standards and ethical requirements; plan and perform the audit to obtain reasonable assurance about whether the Financial Statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Financial Statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and presentation of Financial Statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Management, as well as evaluating the overall presentation of the Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Auditor's opinion

In our opinion, the Financial Statements give a true and fair view, in all material respects, of the financial position of Hanoi CPC1 Pharmaceutical Joint Stock Company as at 31 December 2024, its operations results and its cash flows for the fiscal year ended as at 31 December 2024 in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of Financial Statements.

Other matter

The Company's financial statements for the fiscal year ended 31 December 2023 have been audited by the Auditor and VACO Auditing Co., Ltd. The auditor has issued a full acceptance opinion on this financial statement as of 13 March 2024.

AASC Auditing Firm Company Limited



Vu Xuan Bien

Deputy General Director

Registered Auditor No. 0743-2023-002-1

Hanoi, 29 March 2025



Pham Thi Xuan Thu

Auditor

Registered Auditor No. 1462-2023-002-1

STATEMENT OF FINANCIAL POSITION

As at 31 December 2024

Code	ASSETS	Note	31/12/2024 VND	01/01/2024 VND
100	A. CURRENT ASSETS		831,625,331,586	705,633,103,141
110	I. Cash and cash equivalents	3	39,923,026,642	79,832,556,707
111	1. Cash		5,923,026,642	6,832,556,707
112	2. Cash equivalents		34,000,000,000	73,000,000,000
120	II. Short-term investments	4	5,000,000,000	-
123	1. Held-to-maturity investments		5,000,000,000	-
130	III. Short-term receivables		323,331,711,265	244,435,832,551
131	1. Short-term trade receivables	5	294,178,973,988	219,465,445,787
132	2. Short-term prepayments to suppliers	6	26,056,029,675	23,498,253,552
136	3. Other short-term receivables	7	3,227,759,971	1,921,484,299
137	4. Provision for short-term doubtful debts		(131,052,369)	(449,351,087)
140	IV. Inventories	9	457,806,030,430	374,890,147,357
141	1. Inventories		458,576,003,182	375,905,851,298
149	2. Provision for devaluation of inventories		(769,972,752)	(1,015,703,941)
150	V. Other short-term assets		5,564,563,249	6,474,566,526
151	1. Short-term prepaid expenses	13	4,283,103,450	3,573,333,782
152	2. Deductible VAT		1,279,022,332	2,899,628,319
153	3. Taxes and other receivables from the State budget	17	2,437,467	1,604,425
200	B. NON-CURRENT ASSETS		450,804,079,781	376,701,606,625
210	I. Long-term receivables		3,576,969,012	3,005,883,684
216	1. Other long-term receivables	7	3,576,969,012	3,005,883,684
220	II. Fixed assets		372,804,359,218	329,273,420,730
221	1. Tangible fixed assets	11	358,103,670,008	314,272,549,593
222	- Historical costs		670,397,525,616	557,905,532,916
223	- Accumulated depreciation		(312,293,855,608)	(243,632,983,323)
227	2. Intangible fixed assets	12	14,700,689,210	15,000,871,137
228	- Historical costs		21,759,934,763	21,379,934,763
229	- Accumulated amortization		(7,059,245,553)	(6,379,063,626)
240	III. Long-term assets in progress	10	17,120,938,691	11,143,709,868
242	1. Construction in progress		17,120,938,691	11,143,709,868
260	IV. Other long-term assets		57,301,812,860	33,278,592,343
261	1. Long-term prepaid expenses	13	57,301,812,860	33,278,592,343
270	TOTAL ASSETS		1,282,429,411,367	1,082,334,709,766

STATEMENT OF FINANCIAL POSITION

As at 31 December 2024

(continued)

Code	CAPITAL	Note	31/12/2024 VND	01/01/2024 VND
300	C. LIABILITIES		307,884,788,110	291,561,152,689
310	I. Current liabilities		276,833,027,509	242,968,982,159
311	1. Short-term trade payables	15	79,521,046,475	62,516,567,918
312	2. Short-term prepayments from customers	16	32,612,600,526	19,597,679,482
313	3. Taxes and other payables to State budget	17	17,702,181,709	3,991,306,302
314	4. Payables to employees		65,684,780,139	56,439,965,045
315	5. Short-term accrued expenses	18	1,013,834,994	893,207,127
319	6. Other short-term payments	19	11,717,491,887	4,793,964,720
320	7. Short-term borrowings and finance lease liabilities	14	41,694,687,517	57,980,515,514
321	8. Provisions for short-term payables		-	15,000,000,000
322	9. Bonus and welfare fund		26,886,404,262	21,755,776,051
330	II. Non-current liabilities		31,051,760,601	48,592,170,530
337	1. Other long-term payables	19	131,500,000	138,000,000
338	2. Long-term borrowings and finance lease liabilities	14	30,450,000,000	43,485,000,000
343	3. Science and technology development fund		470,260,601	4,969,170,530
400	D. OWNER'S EQUITY		974,544,623,257	790,773,557,077
410	I. Owner's equity	21	974,544,623,257	790,773,557,077
411	1. Contributed capital		162,290,420,000	162,290,420,000
411a	- Ordinary shares with voting rights		162,290,420,000	162,290,420,000
412	2. Share Premium		9,442,260,000	9,442,260,000
418	3. Development and investment funds		94,353,394,407	94,353,394,407
421	4. Retained earnings		708,458,548,850	524,687,482,670
421a	- Retained earnings accumulated to previous year		471,226,389,269	307,791,266,370
421b	- Retained earnings of the current year		237,232,159,581	216,896,216,300
440	TOTAL CAPITAL		1,082,429,411,367	1,082,334,709,766

Nguyen Thi Xuan Hoan
Preparer
Hanoi, 29 March 2025

Dang Thi Thu Thuy
Chief Accountant



Le Nam Thang
Chairman of the Board of Directors

STATEMENT OF INCOME
Year 2024

Code	ITEMS	Note	Year 2024 VND	Year 2023 VND
01	1. Revenue from sales of goods and rendering of services	23	1,295,750,110,212	1,115,576,290,306
02	2. Revenue deductions	24	2,497,819,877	2,091,090,987
10	3. Net revenue from sales of goods and rendering of services		1,293,252,290,335	1,113,485,199,319
11	4. Cost of goods sold and services rendered	25	612,508,303,148	501,640,316,408
20	5. Gross profit from sales of goods and rendering of services		680,743,987,187	611,844,882,911
21	6. Financial income	26	3,167,719,961	1,197,769,146
22	7. Financial expenses	27	7,766,770,939	10,101,923,142
23	<i>In which: Interest expenses</i>		5,813,362,358	8,981,360,213
25	8. Selling expenses	28	374,447,862,401	331,105,212,763
26	9. General and administrative expense	29	37,644,884,483	39,067,247,027
30	10. Net profit from operating activities		264,052,189,325	232,768,269,125
31	11. Other income		534,397,417	367,795,909
32	12. Other expense	30	587,548,852	1,797,934,459
40	13. Other profit		(53,151,435)	(1,430,138,550)
50	14. Total net profit before tax		263,999,037,890	231,338,130,575
51	15. Current corporate income tax expenses	31	26,766,878,309	14,441,914,275
52	16. Deferred corporate income tax expenses		-	-
60	17. Profit after corporate income tax		237,232,159,581	216,896,216,300
70	18. Basic earnings per share	32	13,057	11,571

Nguyen Thi Xuan Hoan
Preparer
Hanoi, 29 March 2025

Dang Thi Thu Thuy
Chief Accountant

Le Nam Thang
Chairman of the Board of Directors



STATEMENT OF CASH FLOWS

Year 2024
(Direct method)

Code	ITEMS	Note	Year 2024	Year 2023
			VND	VND
	I. CASH FLOWS FROM OPERATING ACTIVITIES			
01	1. Proceeds from sales and services rendered and other revenues		1,294,234,128,691	1,164,633,465,796
02	2. Expenditures paid to suppliers		(782,856,093,166)	(664,010,387,972)
03	3. Expenditures paid to employees		(289,524,944,689)	(256,093,704,364)
04	4. Interest paid		(5,859,268,495)	(9,350,429,248)
05	5. Corporate income tax paid		(13,894,743,114)	(20,091,498,275)
06	6. Other proceeds from operating activities		42,450,103,971	26,390,400,552
07	7. Other expenditures on operating activities		(124,307,870,056)	(80,316,675,147)
20	<i>Net cash flows from operating activities</i>		<i>120,241,313,142</i>	<i>161,161,171,342</i>
	II. CASH FLOWS FROM INVESTING ACTIVITIES			
21	1. Purchase or construction of fixed assets and other long-term assets		(102,509,036,403)	(43,887,150,317)
23	2. Loans and purchase of debt instruments from other entities		(10,000,000,000)	-
24	3. Collection of loans and resale of debt instrument of other entities		5,000,000,000	-
27	4. Interest and dividend received		1,521,884,737	320,229,027
30	<i>Net cash flows from investing activities</i>		<i>(105,987,151,666)</i>	<i>(43,566,921,290)</i>
	III. CASH FLOWS FROM FINANCING ACTIVITIES			
33	1. Proceeds from borrowings		103,489,697,885	120,681,666,391
34	2. Repayment of principal		(133,397,027,719)	(169,197,863,909)
36	3. Dividends or profits paid to owners		(24,343,563,000)	(12,991,232,800)
40	<i>Net cash flows from financing activities</i>		<i>(54,250,892,834)</i>	<i>(61,507,430,318)</i>
50	Net cash flows in the year		(39,996,731,358)	56,086,819,734
60	Cash and cash equivalents at beginning of the year		79,832,556,707	23,651,511,937
61	Effect of exchange rate fluctuations		87,201,293	94,225,036
70	Cash and cash equivalents at end of the year	3	39,923,026,642	79,832,556,707

Nguyen Thi Xuan Hoan
Preparer
Hanoi, 29 March 2025

Dang Thi Thu Thuy
Chief Accountant

Le Nam Thang
Chairman of the Board of Directors



NOTES TO THE FINANCIAL STATEMENTS

Year 2024

1. GENERAL INFORMATION

Form of ownership

CPC1 Hanoi Pharmaceutical Joint Stock Company was established and operated under the Certificate of Business Registration of Joint Stock Company No. 0103039694 issued by the Hanoi Department of Planning and Investment for the first time on 5 August 2009, registered for the 16th change on 23 March 2023.

The Company's head office is located at: Ha Binh Phuong Industrial Cluster, Van Binh Commune, Thuong Tin District, Hanoi.

Company's Charter capital is VND 162,290,420,000, actual contributed Charter capital by 31 December 2024 is VND 162,290,420,000; equivalent to 16,229,042 shares with the price of VND 10,000 per share.

The number of employees of the Company as at 31 December 2024 was 1,871 (as at 01 January 2024: 1,654).

Business field

Production and trading of drugs, pharmaceutical chemicals and medicinal materials.

The Company's operation in the fiscal year that affects the Financial Statements

In 2024, the Company promotes sales policies, causing the output of goods and finished products sold to increase compared to the previous year. However, the increase in input material costs this year makes the growth rate of cost faster than the growth rate of revenue. This led to an increase in total revenue and total cost of capital this year of VND 180,173,819,906 and VND 110,867,986,740, respectively, with an increase of 16.15% and 22.10% compared to the previous year. Since then, the gross profit in sales and service provision this year increased by VND 68,899,104,276, corresponding to an increase of 11,261% compared to the previous year.

In addition, this year the Company has partially settled loans, so interest expenses have decreased. Overall, the above factors made the profit after corporate income tax increase by VND 20,335,943,282 with an increase rate of 9.37% compared to the previous year.

Corporate structure

The Company's member entities are as follows:

The Company's member entities are as follows:	Address	Main business activities
CPC1 Hanoi Pharmaceutical Joint Stock Company - Hanoi Branch	No. 356A Giai Phong, Phuong Liet, Thanh Xuan, Hanoi	Trading in drugs, pharmaceutical chemicals and medicinal materials
CPC1 Hanoi Pharmaceutical Joint Stock Company - Da Nang Branch, Warehouse in Da Nang	Street No. 2, Hoa Khanh Industrial Park, Hoa Khanh Ward, Lien Chieu District, Da Nang City	Trading in drugs, pharmaceutical chemicals and medicinal materials
CPC1 Hanoi Pharmaceutical Joint Stock Company - Ho Chi Minh Branch	No. 26-28 Han Mo Tu Street, Tan Thanh Ward, Tan Phu District, Ho Chi Minh City	Trading in drugs, pharmaceutical chemicals and medicinal materials
Representative Office of CPC1 Hanoi Pharmaceutical Joint Stock Company	No. 78/4/24 Phan Dinh Phung, Tan Thanh Ward, Tan Phu District, Ho Chi Minh City	Trading in drugs, pharmaceutical chemicals and medicinal materials

The company has the following business locations:

Name of business location	Address	Main Business Activities
Business location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Thanh Hoa	MB2125 Lot N27 + N28 Le Hien Tong Street, Dong Ve Ward, Thanh Hoa City, Thanh Hoa Province	Trading in drugs, pharmaceutical chemicals and medicinal materials
Business location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Hai Phong	HA apartment. S01 Vinhomes Marina Urban Area, Vinh Niem Ward, Le Chan District, Hai Phong City	Trading in drugs, pharmaceutical chemicals and medicinal materials
Business location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Nghe An	Apartment No. 109, 12-storey apartment building in New Urban Area, West Avenue VI.Lenin, Hamlet 19, Nghi Phu Commune, Vinh City, Nghe An Province	Trading in drugs, pharmaceutical chemicals and medicinal materials
Business location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Khanh Hoa	Land Lot No. 4, Street No. 93, Thai Hung Urban Area (Package 05 My Gia Urban Area), Vinh Thai Commune, Nha Trang City, Khanh Hoa Province	Trading in drugs, pharmaceutical chemicals and medicinal materials
Business location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Can Tho	Land plot No. 2158, map sheet No. 1, street No. 3, Residential Lot No. 11B, Nam Can Tho urban area, Phu Thu ward, Cai Rang district, Can Tho city	Trading in drugs, pharmaceutical chemicals and medicinal materials
Business location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Dak Lak	Land Lot No. 2263, 2264, Map No. 19, Tan Loi Ward, Buon Ma Thuot City, Dak Lak Province	Trading in drugs, pharmaceutical chemicals and medicinal materials
Business location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Hanoi	1st, 2nd, 3rd floors of Vinh Quang Group Building, Lot DX, Southwest urban area of Linh Dam Lake, Thinh Liet Ward, Hoang Mai District, Hanoi City	Trading in drugs, pharmaceutical chemicals and medicinal materials

2. ACCOUNTING SYSTEM AND ACCOUNTING POLICY**2.1. Accounting period and accounting currency**

Annual accounting period commences from 1 January and ends as at 31 December.

The Company maintains its accounting records in Vietnam Dong (VND).

2.2. Standards and Applicable Accounting Policies*Applicable Accounting Policies*

The Company applies Corporate Accounting System issued under the Circular No. 200/2014/TT-BTC dated 22 December 2014 by the Ministry of Finance and the Circular No. 53/2016/TT-BTC dated 21 March 2016 issued by Ministry of Finance amending and supplementing some articles of the Circular No. 200/2014/TT-BTC .

Declaration of compliance with Accounting Standards and Accounting System

The Company applies Vietnamese Accounting Standards and supplementary documents issued by the State. Financial Statements are prepared and presented in accordance with regulations of each standard and supplementary document as well as with current Accounting Standards and Accounting System.

2.3. Basis for preparation of Financial Statements

Financial Statements are presented based on historical cost principle.

Financial Statements of the Company are prepared based on summarization of transactions incurred, then recorded into accounting books of dependent accounting entities and at the offices of the Company.

2.4. Accounting estimates

The preparation of Financial Statements in conformity with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and legal regulations relating to financial reporting requires the Board of Management to make estimates and assumptions that affect the reported amounts of liabilities, assets and disclosures of contingent liabilities and assets at the date of the separate financial statements and the reported amounts of revenues and expenses during the fiscal year.

The estimates and assumptions that have a material impact in the Financial Statements include:

- Provision for bad debts;
- Provision for devaluation of inventory;
- Estimated allocation of prepaid expenses;
- Estimated useful life of fixed assets;
- Classification and provision of financial investments;
- Estimated income tax.

Such estimates and assumptions are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Company and that are assessed by the Board of Management to be reasonable under the circumstances.

2.5. Financial instruments*Initial recognition***Financial assets**

Financial assets of the Company include cash, cash equivalents, trade receivables, other receivables, lending loans. At initial recognition, financial assets are identified by purchasing price/issuing cost plus other expenses directly related to the purchase and issuance of those assets.

Financial liabilities

Financial liabilities of the Company include borrowings, trade payables, other payables and accrued expenses. At initial recognition, financial liabilities are determined by issuing price plus other expenses directly related to the issuance of those liabilities.

Subsequent measurement after initial recognition

Financial assets and financial liabilities are not revalued according to fair value at the end of the year because the Circular No.210/2009/TT-BTC and prevailing statutory regulations require to present Financial statements and Notes to financial instruments but not provide any relevant instruction for assessment and recognition of fair value of financial assets and financial liabilities.

2.6. Foreign currency transactions

Foreign currency transactions during the year are translated into Vietnam Dong using the actual rate at transaction date.

Actual exchange rate when revaluing monetary items denominated in foreign currencies at the reporting date of Financial Statements is determined under the following principles:

- For asset accounts, applying the bid rate of the commercial bank where the Company regularly conducts transaction;
- For cash deposited in bank, applying the bid rate of the commercial bank where the Company opens its foreign currency accounts;
- For liability accounts, applying the offer rate of the commercial bank where the Company regularly conducts transactions.

All exchange differences arising as a result of transactions or revaluation at the balance sheet date shall be recorded into the financial income or expense in the year.

2.7. Cash and cash equivalents

Cash comprises cash on hand, demand deposits.

Cash equivalents are short-term investments with the maturity of not over than 3 months from the date of investment, that are highly liquid and readily convertible into known amount of cash and that are subject to an insignificant risk of conversion into cash.

2.8. Receivables

The receivables shall be recorded in details in terms of due date, entities receivable, types of currency and other factors according to requirements for management of the Company. The receivables shall be classified into short-term receivables or long-term receivables on the financial statements according to their remaining terms at the reporting date.

The provision for doubtful debts is made for receivables that are overdue under an economic contract, a loan agreement, a contractual commitment or a promissory note and for receivables that are not due but difficult to be recovered. Accordingly, the provisions for overdue debts shall be based on the due date stipulated in the initial sale contract, exclusive of the debt rescheduling between contracting parties and the case where the debts are not due but the debtor is in bankruptcy, in dissolution, or missing and making fleeing or estimating the possible losses.

2.9. Inventories

Inventories are initially recognized at original cost including purchase price, processing cost and other costs incurred in bringing the inventories to their location and condition at the time of initial recognition. After initial recognition, at the reporting date, inventories are stated at the lower of cost and net realizable value.

Net realizable value is estimated based on the selling price of the inventory minus the estimated costs for completing the products and the estimated costs needed for their consumption.

The cost of inventory is calculated using weighted average method.

Inventory is recorded by perpetual method.

Provision for devaluation of inventories made at the end of the year is based on the excess of original cost of inventory over their net realizable value.

2.10. Fixed assets

Tangible fixed assets and intangible fixed assets are initially stated at the historical cost. During the using time, tangible fixed assets and intangible fixed assets are recorded at cost, accumulated depreciation and carrying amount.

Subsequent measurement after initial recognition

If these costs augment future economic benefits obtained from the use of tangible fixed assets are extended to their initial standards conditions, these costs are capitalized as an incremental in their historical cost.

Other costs incurred after tangible fixed assets have been put into operation such as repair, maintenance and overhaul costs are recognized in the Statement of Income in the year in which the costs are incurred.

Fixed assets are depreciated using the straight-line method over their estimated useful lives as follows:

- Buildings, structures	05 - 45 years
- Machinery, equipment	03 - 15 years
- Vehicles, Transportation equipment	04 - 10 years
- Office equipment and furniture	03 - 05 years
- Other fixed assets	02 - 12 years
- Land use rights	45 years
- Management software	03 years

2.11. Construction in progress

Construction in progress includes fixed assets which is being purchased and constructed as at the balance sheet date and is recognised in historical cost. This includes costs of construction, installation of equipment and other direct costs.

2.12. Operating lease

Operating lease is fixed asset leasing in which a significant portion of the risks and rewards of ownership are retained by the lessor. Payments made under operating leases are charged to income statement on a straight-line basis over the period of the lease.

2.13. Prepaid expenses

The expenses incurred but related to operating results of several accounting periods are recorded as prepaid expenses and are allocated to the operating results in the following accounting periods.

The calculation and allocation of long-term prepaid expenses to operating expenses in each accounting period should be based on the nature of those expenses to select a reasonable allocation method and criteria.

Types of prepaid expenses include:

- Prepaid land expenses include prepaid land rental, including those related to leased land for which the Company has received certificate of land use right but not eligible for recording as intangible fixed asset in accordance with the Circular No. 45/2013/TT-BTC dated 25 April 2013 issued by the Ministry of Finance guiding regulation on management, use and depreciation of fixed assets and other expenses related to ensure for the use of leased land. These expenses are recognized in the statement of income on a straight-line basis according to the lease term of the contract.
- Tools and supplies include assets which are possessed by the Company in an ordinary course of business, with historical cost of each asset less than 30 million dongs and therefore not eligible for recording as fixed asset under current legal regulations. The historical cost of tools and supplies are allocated on the straight-line basis from 6 to 36 months.
- Repair and maintenance costs shall be recorded at the historical cost and allocated according to the straight-line method to the cost of not exceeding 03 years.
- Office rental costs and insurance costs are allocated according to the straight-line method from 06 months to 12 months.
- Other prepaid expenses shall be recorded at historical cost and allocated according to the straight-line method for a useful period of not more than 03 years.

2.14. Payables

The payables shall be recorded in details in terms of due date, entities payable, types of currency and other factors according to the requirements for management of the Company. The payables shall be classified into short-term payables or long-term payables on the financial statements according to their remaining terms at the reporting date.

2.15. Borrowings

Borrowings and finance lease liabilities shall be recorded in details in terms of lending entities, loan agreement and terms of borrowings and finance lease liabilities. In case of borrowings or liabilities denominated in foreign currency, they shall be recorded in details in terms of types of currency.

2.16. Borrowing costs

Borrowing costs are recognized as operating expenses in the year, in which it is incurred excepting those which are directly attributable to the construction or production of a qualifying asset are capitalized as part of the cost of that asset in accordance with VAS No. 16 "Borrowing costs". Besides, regarding borrowings serving the construction of fixed assets and investment properties, the interests shall be capitalized even when the construction duration is under 12 months.

2.17. Accrued expenses

Payables for goods and services that have been received from the seller or provided to the buyer in the reporting year but have not actually been paid and other payables such as interest expenses, payable loans, personal income tax expenses, etc. shall be recorded in production and business expenses of the reporting year.

The recording of accrued expenses as operating expenses during the year shall be carried out under the matching principle between revenues and expenses during the year. Accrued expenses are settled with actual expenses incurred. The difference between accrued and actual expenses is reverted.

2.18. Owner's equity

Owner's equity is stated at actually contributed capital of owners.

Share premium is recorded at the difference between the par value with costs directly attributable to the issuance of shares and issue price of shares (including the case of re-issuing treasury shares) and can be a positive premium (if the issue price is higher than par value and costs directly attributable to the issuance of shares) or negative premium (if the issue price is lower than par value and costs directly attributable to the issuance of shares).

Retained earnings are used to present the Company's operating results (profit, loss) after corporate income tax and profit appropriation or loss handling of the Company.

Dividends to be paid to shareholders are recognised as a payable in Statement of Financial position after the announcement of dividend payment from fiscal year and announcement of cut-off date for dividend payment of Vietnam Securities Depository and Clearing Corporation.

2.19. Revenues

Revenue is recognized when the Company is able to receive definitively identifiable economic benefits. Revenue is determined according to the fair value of the collected amounts or will be collected after deducting commercial discounts, discounts on the sale of goods sold, and returned goods sold. The following specific recognition conditions must also be met when recording revenue:

Revenue from sale of goods:

- The majority of risks and benefits associated with the right to own the products or goods have been transferred to the buyer;
- The company no longer holds the right to manage the goods as the goods owner, or the right to control the goods;

Revenue from rendering of services:

- The percentage of completion of the transaction at the Balance sheet date can be measured reliably.

Financial income

Financial incomes include income from assets yielding interest, royalties, dividends and other financial gains by the company shall be recognised when the two conditions are satisfied:

- It is probable that the economic benefits associated with the transaction will flow to the Company;
- The amount of the revenue can be measured reliably.

Dividend income shall be recognised when the Company's right to receive dividend is established.

2.20. Revenue deductions

Revenue deductions from sales of goods and rendering of services arising in the Previous year include: Trade discounts and sales returns.

Trade discount and sales return incurred in the same period of sale of goods and rendering of services are recorded as a decrease in revenue in the incurring period. In case goods and services are sold in the previous periods, but until the next period they are incurred as deductible items, the Company records the decrease in revenue under the following principles: If it is incurred prior to the issuance of Financial Statements, it is then recorded as a decrease in revenue on the Financial Statements of the reporting period (the previous period); and if it is incurred after the issuance of Financial Statements, it is recorded as a decrease in revenue of incurring period (the next period).

2.21. Cost of goods sold and services rendered

Cost of goods sold and services rendered are cost of finished goods, merchandises, materials sold or services rendered during the year, and recorded on the basis of matching with revenue and on a prudence basis. Cases of loss of materials and goods exceeded the norm, labour cost and fixed manufacturing overheads not allocated to the value of inventory, provision for devaluation of inventory, abnormal expenses and losses of inventories after deducting the responsibility of collective and individuals concerned, etc. is recognized fully and promptly into cost of goods sold in the year even when products and goods have not been determined as sold.

2.22. Financial expenses

Items recorded into financial expenses comprise:

- Borrowing costs;
- Exchange rate loss.

The above items are recorded by the total amount arising in the year without offsetting against financial income.

2.23. Corporate income tax**a) Current corporate income tax expenses**

Current corporate income tax expenses are determined based on taxable income during the year and current corporate income tax rate.

b) Tax incentives

The Company is enjoying tax incentives as follows:

The company is a science and technology enterprise certified under Certificate No. 44/DNKHCN issued for the first time on 19 July 2018 by the Hanoi Department of Science and Technology. Accordingly, the Company is entitled to incentives for exemption and reduction of corporate income tax according to the provisions of Article 12, Decree No. 13/2019/ND-CP dated 01 February 2019 of the Government on science and technology enterprises if it meets the conditions on revenue of products formed from scientific and technological results reaching a minimum rate of 30% of the total revenue of the enterprise karma. Therefore, enterprises are exempt from corporate income tax for 04 years and reduce 50% of payable tax for the next 9 years from 2018.

c) Current corporate income tax rate

For the fiscal year ended as at 31 December 2024, The Company applies the corporate income tax rate of 20% for the operating activities which has taxable income.

2.24. Earnings per share

Basic earnings per share are calculated by dividing net profit or loss after tax for the year attributable to ordinary shareholders of the Company (after adjusting for the bonus and welfare fund and allowance for Board of Management) by the weighted average number of ordinary shares outstanding during the year.

2.25. Related Parties

The parties are regarded as related parties if that party has the ability to control or significantly influence the other party in making decisions about the financial policies and activities. The Company's related parties include:

- Companies, directly or indirectly through one or more intermediaries, having control over the Company or being under the control of the Company, or being under common control with the Company, including the Company's parent, subsidiaries and associates;
- Individuals, directly or indirectly, holding voting power of the Company that have a significant influence on the Company, key management personnel including directors and employees of the Company, the close family members of these individuals;
- Enterprises that the above-mentioned individuals directly or indirectly hold an important part of the voting power or have significant influence on these enterprises.

In considering the relationship of related parties to serve for the preparation and presentation of Financial Statements, the Company should consider the nature of the relationship rather than the legal form of the relationship.

2.26. Segment information

Because the Company operates mainly in the field of production and trading of drugs, pharmaceutical chemicals and medicinal materials in the territory of Vietnam, the Company does not make Segment Reports by business field and geographical area.

3. CASH AND CASH EQUIVALENTS

	31/12/2024	01/01/2024
	VND	VND
- Cash on hand	895,537,197	764,005,325
- Demand deposits	5,027,489,445	6,068,551,382
- Cash equivalents (*)	34,000,000,000	73,000,000,000
	39,923,026,642	79,832,556,707

(*) As of 31 December 2024, cash equivalents are term deposits from 1 week to 3 months with a value of VND 34,000,000,000 deposited at Asia Commercial Joint Stock Bank and VIB International Bank with interest rates from 0.5%/year to 3.7%/year.

4. SHORT-TERM FINANCIAL INVESTMENTS

	31/12/2024		01/01/2024	
	Original cost	Provision	Original cost	Provision
	VND	VND	VND	VND
Short-term investments				
- Term deposits	5,000,000,000	-	-	-
	5,000,000,000	-	-	-

On 31 December 2024, the investment held until maturity is a 6-month term deposit contract worth VND 5,000,000,000 deposited at Asia Commercial Joint Stock Bank with an interest rate of 3.9%/year.

5. SHORT-TERM TRADE RECEIVABLES

	31/12/2024		01/01/2024	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
Related parties	9,954,555,937	-	4,855,510,149	-
- Tan Thinh Pharmaceutical Co., Ltd.	2,923,683,600	-	2,826,296,797	-
- VNP Pharmaceutical Co., Ltd.	7,016,907,337	-	2,029,213,352	-
- CPC1 Central Pharmaceutical Joint Stock Company - Quang Ninh Branch	13,965,000	-	-	-
Other	284,224,418,051	-	214,609,935,638	(318,298,718)
- Cho Ray Hospital	6,953,647,600	-	3,031,814,600	-
- Binh Minh Pharmaceutical Co., Ltd.	3,885,418,637	-	2,221,671,255	-
- Thuan Phat Production and Development Investment Co., Ltd.	24,848,092,599	-	17,254,730,011	-
- Novopharm Co., Ltd.	2,190,666,660	-	2,753,140,813	-
- INQ Pharma Co., Ltd.	3,599,507,249	-	2,887,127,145	-
- Hung Vuong Medical Equipment and Trading Joint Stock Company	7,791,276,489	-	-	-
- Others	234,955,808,817	-	186,461,451,814	(318,298,718)
	294,178,973,988	-	219,465,445,787	(318,298,718)

6. SHORT-TERM PREPAYMENTS TO SUPPLIERS

	31/12/2024		01/01/2024	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
- Phu Quy Construction and Infrastructure Joint Stock Company	851,358,761	-	-	-
- Sao Viet Advertising and Communication Joint Stock Company	-	-	2,715,492,600	-
- ANTCONS Construction Co., Ltd.	-	-	1,080,738,000	-
- Qui Long Refrigeration Mechanical and Electrical Engineering Co., Ltd.	5,203,970,160	-	1,079,564,328	-
- Huy Anh Construction and Trading Services Joint Stock Company	1,748,281,844	-	-	-
- Others	18,252,418,910	(131,052,369)	18,622,458,624	(131,052,369)
	26,056,029,675	(131,052,369)	23,498,253,552	(131,052,369)

7. OTHER RECEIVABLES

	31/12/2024		01/01/2024	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
a) Short-term				
<i>a.1) Details by content</i>				
- Advances	2,233,936,114	-	1,048,034,377	-
- Mortgages	684,566,797	-	598,310,615	-
- Other receivables	309,257,060	-	275,139,307	-
	3,227,759,971	-	1,921,484,299	-
<i>a.2) Detail by object</i>				
<i>Related parties</i>	51,526,600	-	50,000,000	-
- CPC1 Central Pharmaceutical Joint Stock Company	50,000,000	-	50,000,000	-
- Tan Thinh Pharmaceutical Co., Ltd.	1,526,600	-	-	-
<i>Other</i>	3,176,233,371	-	1,871,484,299	-
- Tho Thanh Tam	285,908,452	-	523,536,005	-
- Other receivables	2,890,324,919	-	1,347,948,294	-
	3,227,759,971	-	1,921,484,299	-
b) Long-term				
<i>b.1) Details by content</i>				
- Mortgages	3,576,969,012	-	3,005,883,684	-
	3,576,969,012	-	3,005,883,684	-
<i>b.2) Detail by object</i>				
<i>Related parties</i>	400,000,000	-	400,000,000	-
- CPC1 Central Pharmaceutical Joint Stock Company	400,000,000	-	400,000,000	-
<i>Other</i>	3,176,969,012	-	2,605,883,684	-
- Asia Commercial Joint Stock Bank (ACB)	1,732,540,149	-	1,732,540,149	-
- Binh Tien Consumer Goods Manufacturing Co., Ltd.	600,000,000	-	600,000,000	-
- Other deposits and collaterals	844,428,863	-	273,343,535	-
	3,576,969,012	-	3,005,883,684	-

8. DOUBTFUL DEBTS

	31/12/2024		01/01/2024	
	Original cost	Recoverable value	Original cost	Recoverable value
	VND	VND	VND	VND
- Total value of receivables and debts that are overdue or not due but difficult to be recovered				
Trade receivables	-	-	441,463,704	123,164,986
+ Gia Lai Pharmaceutical and Medical Supplies Joint Stock Company	-	-	200,697,000	60,209,100
+ Other subjects	-	-	240,766,704	62,955,886
Prepayments to suppliers	131,052,369	-	131,052,369	-
+ Viet Scooter Joint Stock Company	127,050,000	-	127,050,000	-
+ Hoa Nhon Printing Co., Ltd.	4,002,369	-	4,002,369	-
	131,052,369	-	572,516,073	123,164,986

9. INVENTORIES

	31/12/2024		01/01/2024	
	Original cost	Provision	Original cost	Provision
	VND	VND	VND	VND
- Goods in transit	13,037,207,591	-	33,486,833,543	-
- Raw material	137,708,935,583	(171,425,088)	135,042,894,177	(570,441,192)
- Tools, supplies	127,690,574	-	6,049,341	-
- Work in progress	10,331,775,450	-	6,718,468,042	-
- Finished goods	152,119,377,011	(598,547,664)	120,932,220,529	(445,262,749)
- Goods	145,251,016,973	-	79,719,385,666	-
	458,576,003,182	(769,972,752)	375,905,851,298	(1,015,703,941)

10. LONG-TERM ASSET IN PROGRESS

	31/12/2024	01/01/2024
	VND	VND
- Procurement of fixed assets	2,553,964,000	336,123,372
Technology piping system project	1,872,114,000	-
Employee check-in system project	531,700,000	-
Other Shopping	150,150,000	336,123,372
- Construction in progress	11,071,944,358	10,780,833,200
Factory project in Ha Binh Phuong Industrial Cluster (*)	10,238,726,758	9,947,615,600
Tan Phu Trung factory project	833,217,600	833,217,600
- Major repairs of fixed assets	3,495,030,333	26,753,296
Factory renovation project	3,495,030,333	-
Other projects	-	26,753,296
	17,120,938,691	11,143,709,868

(*) This is a project to invest and build a factory to manufacture drugs, functional foods, and medical equipment GMP according to EU standards. The project is built at the headquarters campus in Ha Binh Phuong Industrial Cluster, Van Binh Commune, Thuong Tin District, Hanoi. The purpose of investment is to improve production productivity, expand the scale of facilities, and meet the Company's production and business needs in the next time. Investment capital comes from own capital and capital mobilized from credit institutions.

Hanoi CPC1 Pharmaceutical Joint Stock Company
Financial Statements

Ha Binh Phuong Industrial Cluster, Van Binh Commune, Thuong Tin District, Hanoi

For the fiscal year ended as at 31 December 2024

11. TANGIBLE FIXED ASSETS

	Buildings, structures	Machinery, equipment	Vehicles, transportation equipment	Office equipment and furniture	Others	Total
	VND	VND	VND	VND	VND	VND
Historical cost						
Beginning balance	120,638,588,842	389,097,897,086	28,957,896,278	921,124,091	18,290,026,619	557,905,532,916
- Purchase in the year	-	64,676,313,885	1,588,392,480	-	6,657,217,005	72,921,923,370
- Completed construction investment	21,579,110,943	17,990,958,387	-	-	-	39,570,069,330
Ending balance of the year	142,217,699,785	471,765,169,358	30,546,288,758	921,124,091	24,947,243,624	670,397,525,616
Accumulated depreciation						
Beginning balance	26,631,981,055	190,143,220,880	14,279,563,008	71,893,709	12,506,324,671	243,632,983,323
- Depreciation in the year	4,963,536,518	56,755,021,880	4,391,662,972	302,426,928	2,248,223,987	68,660,872,285
Ending balance of the year	31,595,517,573	246,898,242,760	18,671,225,980	374,320,637	14,754,548,658	312,293,855,608
Net carrying amount						
Beginning balance	94,006,607,787	198,954,676,206	14,678,333,270	849,230,382	5,783,701,948	314,272,549,593
Ending balance	110,622,182,212	224,866,926,598	11,875,062,778	546,803,454	10,192,694,966	358,103,670,008

In which:

- The carrying amount of tangible fixed assets pledged as collaterals for borrowings at the end of the year: VND 183,816,297,742.
- Cost of fully depreciated tangible fixed assets but still in use at the end of the year: VND 91,636,780,862.

12. INTANGIBLE FIXED ASSETS

	Land use rights (*)	Computer Software	Total
	VND	VND	VND
Historical cost			
Beginning balance	20,260,434,763	1,119,500,000	21,379,934,763
- Purchase in the year	-	380,000,000	380,000,000
Ending balance of the year	20,260,434,763	1,499,500,000	21,759,934,763
Accumulated amortization			
Beginning balance	5,400,060,815	979,002,811	6,379,063,626
- Amortization in the year	450,314,364	229,867,563	680,181,927
Ending balance of the year	5,850,375,179	1,208,870,374	7,059,245,553
Net carrying amount			
Beginning balance	14,860,373,948	140,497,189	15,000,871,137
Ending balance	14,410,059,584	290,629,626	14,700,689,210

(*) The land use right is valid until May 29, 2057 in Ha Binh Phuong Industrial Park, Van Binh Commune, Thuong Tin District, Hanoi City with a total area of 30,306.3 m² which is being used as the Company's headquarters and GMP-WHO Pharmaceutical Factory with a historical cost of VND 20,260,434,763.

In which:

- The historical cost of intangible fixed assets at the end of the year has been fully depreciated but still in use: VND 1,119,500,000.

13. PREPAID EXPENSES

	31/12/2024	01/01/2024
	VND	VND
a) Short-term prepaid expenses		
- Prepaid expenses of operating lease	1,279,731,556	1,063,920,702
- Office Rental Cost	2,072,400,000	1,172,000,000
- Cost of Insurance	116,912,006	180,068,063
- Others	814,059,888	1,157,345,017
	4,283,103,450	3,573,333,782
b) Long-term prepaid expenses		
- Prepaid land and infrastructure rent in Tan Phu Trung Industrial Park (*)	11,577,908,458	11,964,913,749
- Land use rights in Hoa Khanh Expanded Industrial Park (**)	13,778,380,228	-
- Export tools	20,413,558,074	15,498,428,210
- Repair and maintenance costs	9,486,939,560	4,485,986,067
- Others	2,045,026,540	1,329,264,317
	57,301,812,860	33,278,592,343

(*) Land and infrastructure rent is paid in a lump sum for a land area of 6,596.9 m² in Tan Phu Trung Industrial Park, Tan Phu Trung Commune, Cu Chi District, Ho Chi Minh City with Northwest Saigon Urban Development Joint Stock Company. The land lease period is from the time of signing the official land lease contract to 16 December 2054. The company makes allocation according to the lease period of the contract.

(**) The land use right has a total area of 7,694.0 m² in Hoa Khanh Expanded Industrial Park, Hoa Khanh Bac Ward, Lien Chieu District, Da Nang City under the land and other land-attached assets transfer contract dated 17 October 2024 between CPC1 Hanoi Pharmaceutical Joint Stock Company and Thanh Hoang Chau One Member Co., Ltd. The purpose of buying land is to invest in a warehouse for goods. The land use period under the land use right certificate is until 25 March 2054. The company allocates according to the remaining time of the land use right certificate.

Hanoi CPC1 Pharmaceutical Joint Stock Company
Financial Statements

Ha Binh Phuong Industrial Cluster, Van Binh Commune, Thuong Tin District, Hanoi

For the fiscal year ended as at 31 December 2024

14. BORROWINGS

	01/01/2024		During the year		31/12/2024	
	Outstanding balance	Amount can be paid	Increase	Decrease	Outstanding balance	Amount can be paid
	VND	VND	VND	VND	VND	VND
a) Short-term borrowings						
- Short-term loans	44,620,515,514	44,620,515,514	105,332,333,291	121,258,161,288	28,694,687,517	28,694,687,517
Joint Stock Commercial Bank for Foreign Trade of Vietnam - Nam Thang Long Branch	-	-	14,059,602,787	5,755,461,512	8,304,141,275	8,304,141,275
Asia Commercial Joint Stock Bank - Hanoi Branch - Times City Transaction Office	34,556,650,310	34,556,650,310	85,497,203,486	100,171,547,554	19,882,306,242	19,882,306,242
Military Commercial Joint Stock Bank	10,063,865,204	10,063,865,204	5,775,527,018	15,331,152,222	508,240,000	508,240,000
- Current portion of long-term debts	13,360,000,000	13,360,000,000	13,000,000,000	13,360,000,000	13,000,000,000	13,000,000,000
Asia Commercial Joint Stock Bank - Hanoi Branch - Times City Transaction Office	5,750,000,000	5,750,000,000	5,500,000,000	5,750,000,000	5,500,000,000	5,500,000,000
Joint Stock Commercial Bank for Industry and Trade of Vietnam - Hoang Mai Branch	210,000,000	210,000,000	-	210,000,000	-	-
Joint Stock Commercial Bank for Investment and Development of Vietnam	7,400,000,000	7,400,000,000	7,500,000,000	7,400,000,000	7,500,000,000	7,500,000,000
	57,980,515,514	57,980,515,514	118,332,333,291	134,618,161,288	41,694,687,517	41,694,687,517
b) Long-term borrowings						
Asia Commercial Joint Stock Bank - Hanoi Branch - Times City Transaction Office	14,000,000,000	14,000,000,000	-	5,750,000,000	8,250,000,000	8,250,000,000
Joint Stock Commercial Bank for Industry and Trade of Vietnam - Hoang Mai Branch	245,000,000	245,000,000	-	245,000,000	-	-
Joint Stock Commercial Bank for Investment and Development of Vietnam	42,600,000,000	42,600,000,000	-	7,400,000,000	35,200,000,000	35,200,000,000
	56,845,000,000	56,845,000,000	-	13,395,000,000	43,450,000,000	43,450,000,000
Amount due for settlement within 12 months	(13,360,000,000)	(13,360,000,000)	(13,000,000,000)	(13,360,000,000)	(13,000,000,000)	(13,000,000,000)
Amount due for settlement after 12 months	43,485,000,000	43,485,000,000			30,450,000,000	30,450,000,000

Hanoi CPC1 Pharmaceutical Joint Stock Company **Financial Statements**
Ha Binh Phuong Industrial Cluster, Van Binh Commune, Thuong Tin District, Hanoi **For the fiscal year ended as at 31 December 2024**

Detailed information on short-term borrowings:

	Currency	Interest Rate	Maturity	Loan purpose	Guarantee	31/12/2024	01/01/2024
Joint Stock Commercial Bank for Foreign Trade of Vietnam - Nam Thang Long Branch (Contract No: NTL-HDCV/20020242.24 003)	VND	3.7% - 3.8%	3 - 6 months from the date of disbursement according to debt acceptance contracts	Replenishment of working capital	Unsecured	VND 8,304,141,275	VND -
Asia Commercial Joint Stock Bank - Hanoi Branch - Times City Transaction Office (Contract No: BMA.DN.2184.270324)	USD	3.5% - 4.0%	6 - 8 months from the date of disbursement according to debt acceptance contracts	Replenishment of working capital	Pharmaceutical factory, machinery and equipment in Ha Binh Phuong Industrial Park, Van Binh, Thuong Tin, Hanoi	19,882,306,242	34,556,650,310
Military Commercial Joint Stock Bank (Contract No: 231723.24.061.25377 76.TD)	VND	5.0%	6 months from the date of disbursement according to debt acceptance contracts	Replenishment of working capital	Unsecured	508,240,000	10,063,865,204

28,694,687,517
44,620,515,514

Loans from banks and other credit institutions are secured by mortgage/pledge contracts with capital lenders and have been fully registered for secured transactions.

Detailed information on long-term borrowings:

	Currency	Interest Rate	Date due	Loan purpose	Guarantee	31/12/2024 VND	01/01/2024 VND
Asia Commercial Joint Stock Bank - Hanoi Branch - Times City Transaction Office (Contract No: BMA. DN.328.121217)	VND	8.50%	19/04/2026	Investment in BFS 460-15 technology production line system	BFS 460 machine system and factory, machinery and equipment at the Company	8,250,000,000	14,000,000,000
Joint Stock Commercial Bank for Industry and Trade of Vietnam - Hoang Mai Branch (Contract No: 01/2020-HDCVDADT/NHCT 136-CPC1)	VND	8.1% in the first year, then adjusted	13/02/2025	Buying car	Car	-	245,000,000
Joint Stock Commercial Bank for Investment and Development of Vietnam (Contract No: 01/2021/3383375/HD TC)	VND	7.2% in the first year, then adjust the float periodically 1 year 2 times	07/09/2029	Investment in machinery and equipment for the production of sterile plastic tubes for medicines	Machinery and equipment system for the production of sterile plastic pipes for medicines: - Model 460-15 manufactured in 2022	35,200,000,000	42,600,000,000
Amount due for settlement within 12 months						43,450,000,000	56,845,000,000
Amount due for settlement after 12 months						(13,000,000,000)	(13,000,000,000)
						30,450,000,000	43,845,000,000

Loans from banks and other credit institutions are secured by mortgage/pledge contracts with capital lenders and have been fully registered for secured transactions.

Hanoi CPC1 Pharmaceutical Joint Stock Company

Ha Binh Phuong Industrial Cluster, Van Binh
Commune, Thuong Tin District, Hanoi

Financial Statements

For the fiscal year ended as at 31 December 2024

15. SHORT-TERM TRADE PAYABLES

	31/12/2024		01/01/2024	
	Value	Amount can be paid	Value	Amount can be paid
	VND	VND	VND	VND
<i>Related parties</i>	960,941,016	960,941,016	262,656,072	262,656,072
- Tan Thinh Pharmaceutical Co., Ltd.	960,941,016	960,941,016	262,656,072	262,656,072
<i>Others</i>	78,560,105,459	78,560,105,459	62,253,911,846	62,253,911,846
- Phuong Linh Pharmaceutical Trading Co., Ltd.	9,558,229,368	9,558,229,368	-	-
- Thuan Phat Production and Development Investment Co., Ltd.	363,261,366	363,261,366	1,610,870,438	1,610,870,438
- Novopharm Co., Ltd.	2,087,198,447	2,087,198,447	2,733,712,534	2,733,712,534
- Hung Vuong Medical Equipment and Trading Joint Stock Company	-	-	7,153,524,866	7,153,524,866
- Minh An Pharmaceutical and Cosmetic Joint Stock Company	5,695,342,774	5,695,342,774	-	-
- Others	60,856,073,504	60,856,073,504	50,755,804,008	50,755,804,008
	79,521,046,475	79,521,046,475	62,516,567,918	62,516,567,918

16. SHORT-TERM PREPAYMENTS FROM CUSTOMERS

	31/12/2024	01/01/2024
	VND	VND
- DP Euphar Joint Stock Company	588,000,000	588,000,000
- Phu An Pharmaceutical and Cosmetic Co., Ltd.	176,400,000	258,300,000
- Hoang Son Pharmaceutical Trading Joint Stock Company	738,000,000	525,750,000
- Bao Minh Pharmaceutical Joint Stock Company	251,370,000	-
- Sanophar	2,384,146,730	512,451,000
- Others	28,474,683,796	17,713,178,482
	32,612,600,526	19,597,679,482

Hanoi CPC1 Pharmaceutical Joint Stock Company

Ha Binh Phuong Industrial Cluster, Van Binh Commune, Thuong Tin District, Hanoi

Financial Statements

For the fiscal year ended as at 31 December 2024

17. TAX AND PAYABLES FROM STATE BUDGET

	Tax receivable at the beginning of year	Tax payable at the beginning of year	Tax payable in the year	Tax paid in the year	Tax receivable at the end of the year	Tax payable at the end of the year
	VND	VND	VND	VND	VND	VND
Value-added tax	1,604,425	286,068,716	4,448,821,883	3,948,137,808	2,437,467	787,585,833
Value Added Tax on Imports	-	-	21,332,043,898	21,332,043,898	-	-
Export, import duties	-	-	3,583,629,128	3,583,629,128	-	-
Corporate income tax	-	2,576,300,307	26,766,878,309	13,894,743,114	-	15,448,435,502
Personal income tax	-	1,128,937,279	11,371,026,854	11,033,803,759	-	1,466,160,374
Land tax and land rental	-	-	834,140,506	834,140,506	-	-
Other taxes	-	-	471,646,487	471,646,487	-	-
Fees, charges and other payables	-	-	605,609,219	605,609,219	-	-
	1,604,425	3,991,306,302	69,413,796,284	55,703,753,919	2,437,467	17,702,181,709

The Company's tax settlements are subject to examination by the tax authorities. Because the application of tax laws and regulations on many types of transactions is susceptible to varying interpretations, amounts reported in the Financial Statements could be changed at a later date upon final determination by the tax authorities.

18. SHORT-TERM ACCRUED EXPENSES

	31/12/2024	01/01/2024
	VND	VND
- Interest expense	59,763,750	105,669,887
- Expenses for pre-deduction of PIT payable	946,371,244	786,237,240
- Other accrued expenses	7,700,000	1,300,000
	1,013,834,994	893,207,127

19. OTHER PAYABLES

	31/12/2024	01/01/2024
	VND	VND
a) Short-term		
<i>a.1) Details by content</i>		
- Trade union fee	2,061,323,586	1,970,049,683
- Social insurance	70,696,500	-
- Advance payment for entrusted goods	6,151,817,546	264,000,000
- Retained amounts of officials and employees	3,129,339,675	1,829,641,303
- Others	304,314,580	730,273,734
	11,717,491,887	4,793,964,720
<i>a.2) Detail by object</i>		
<i>Related parties</i>	5,934,817,546	63,000,000
- VNP Pharmaceutical Co., Ltd.	5,871,817,546	-
- Remuneration of the Board of Directors, Supervisory Board	63,000,000	63,000,000
<i>Other</i>	5,782,674,341	4,730,964,720
- Officials and employees	3,129,339,675	1,829,641,303
- Other payables and payables	2,653,334,666	2,901,323,417
	11,717,491,887	4,793,964,720
b) Long-term		
<i>b.1) Details by content</i>		
- Long-term deposits, collateral received	131,500,000	138,000,000
	131,500,000	138,000,000

20. SCIENCE AND TECHNOLOGY DEVELOPMENT FUND

	Year 2024	Year 2023
	VND	VND
Balance at the beginning of the year	4,969,170,530	4,323,091,115
Appropriations in the year	-	3,000,000,000
Use of the year	(4,498,909,929)	(2,353,920,585)
Balance at the end of the year	470,260,601	4,969,170,530

21. OWNER'S EQUITY

a) Changes in owner's equity

	Contributed capital	Share premium	Development and investment funds	Retained earnings	Total
	VND	VND	VND	VND	VND
Beginning balance of previous year	162,290,420,000	9,442,260,000	94,353,394,407	331,872,388,372	597,958,462,779
Profit for previous year	-	-	-	216,896,216,300	216,896,216,300
Profit distribution	-	-	-	(24,081,122,002)	(24,081,122,002)
<i>Dividend Distribution</i>	-	-	-	(12,983,233,600)	(12,983,233,600)
<i>Deduction of bonus funds from the Board of Directors and the Board of Supervision</i>	-	-	-	(56,000,000)	(56,000,000)
<i>Deduction of the Executive Board bonus fund</i>	-	-	-	(4,800,880,663)	(4,800,880,663)
<i>Deduction of welfare reward fund</i>	-	-	-	(6,241,007,739)	(6,241,007,739)
Ending balance of previous year	162,290,420,000	9,442,260,000	94,353,394,407	524,687,482,670	790,773,557,077
Beginning balance of current year	162,290,420,000	9,442,260,000	94,353,394,407	524,687,482,670	790,773,557,077
Profit for this year	-	-	-	237,232,159,581	237,232,159,581
Profit distribution	-	-	-	(53,461,093,401)	(53,461,093,401)
<i>Dividend Distribution</i>	-	-	-	(24,343,563,000)	(24,343,563,000)
<i>Deduction of bonus funds from the Board of Directors and the Board of Supervision</i>	-	-	-	(72,000,000)	(72,000,000)
<i>Deduction of the Executive Board bonus fund</i>	-	-	-	(18,200,719,586)	(18,200,719,586)
<i>Deduction of reward and welfare funds</i>	-	-	-	(10,844,810,815)	(10,844,810,815)
Ending balance of this year	162,290,420,000	9,442,260,000	94,353,394,407	708,458,548,850	974,544,623,257

The distribution of profits is carried out in accordance with the Resolution of the 2024 Annual General Meeting of Shareholders No. 146/2024/NQ-DHDCD dated 05/04/2024.

21. OWNER'S EQUITY

b) Details of Contributed capital

	31/12/2024	Rate	01/01/2024	Rate
	VND	%	VND	%
CPC1 Central Pharmaceutical Joint Stock Company	26,666,660,000	16.43	26,666,660,000	16.43
Le Thi Kim Anh	27,899,990,000	17.19	27,899,990,000	17.19
Nguyen Tien Lung	13,333,330,000	8.22	13,333,330,000	8.22
Le Nam Thang	15,007,540,000	9.25	15,007,540,000	9.25
Nguyen Thanh Binh	31,286,650,000	19.28	31,286,650,000	19.28
Phung Thanh Huong	16,639,990,000	10.25	16,639,990,000	10.25
Others	31,456,260,000	19.38	31,456,260,000	19.38
	162,290,420,000	100	162,290,420,000	100

c) Capital transactions with owners and distribution of dividends and profits

	Year 2024	Year 2023
	VND	VND
Owner's contributed capital		
- At the beginning of year	162,290,420,000	162,290,420,000
- At the ending of year	162,290,420,000	162,290,420,000
Distributed dividends and profit		
- Dividend payable at the beginning of the year	-	7,999,200
- Dividend payable in the year	24,343,563,000	12,983,233,600
+ Dividend payable from last year's profit	24,343,563,000	12,983,233,600
- Dividend paid in cash in the year	(24,343,563,000)	(12,991,232,800)
+ Dividend paid from last year's profit	(24,343,563,000)	(12,991,232,800)
- Dividend payable at the end of the year	-	-

d) Share

	31/12/2024	01/01/2024
	VND	VND
Quantity of Authorized issuing shares	16,229,042	16,229,042
Quantity of issued shares and full capital contribution	16,229,042	16,229,042
- Common shares	16,229,042	16,229,042
Quantity of outstanding shares in circulation	16,229,042	16,229,042
- Common shares	16,229,042	16,229,042
Par value per share (VND)	10,000	10,000

e) Company's reserves

	31/12/2024	01/01/2024
	VND	VND
- Development and investment funds	94,353,394,407	94,353,394,407
	94,353,394,407	94,353,394,407

22. OFF STATEMENT OF FINANCIAL POSITION ITEMS AND OPERATING LEASE COMMITMENT

a) Operating leased assets

<u>Name/Location</u>	<u>Purpose of Lease</u>
- Land plot Lot A5-1, D2 & N2 street, in Zone A5, Tan Phu Trung Industrial Park	Implementation of investment projects
- Land plot in Ha Binh Phuong Industrial Cluster, Van Binh commune, Thuong Tin district, Hanoi	GMP-WHO Pharmaceutical Factory
- No. 356A Giai Phong, Phuong Liet, Thanh Xuan, Hanoi	Hanoi Branch Office
- Street No. 2, Hoa Khanh Industrial Park, Hoa Khanh Ward, Lien Chieu District, Da Nang City	Da Nang branch office, warehouse
- No. 26-28 Han Mo Tu Street, Tan Thanh Ward, Tan Phu District, Ho Chi Minh City	Ho Chi Minh Branch Office
- No. 78/4/24 Phan Dinh Phung, Tan Thanh Ward, Tan Phu District, Ho Chi Minh City	Representative Office
- MB2125 Lot N27 + N28 Le Hien Tong Street, Dong Ve Ward, Thanh Hoa City, Thanh Hoa Province	Business Location
- HA apartment. S01 Vinhomes Marina Urban Area, Vinh Niem Ward, Le Chan District, Hai Phong City	Business Location
- Apartment No. 109, 12-storey apartment building in New Urban Area, West Avenue VI.Lenin, Hamlet 19, Nghi Phu Commune, Vinh City, Nghe An Province	Business Location
- Land Lot No. 4, Street No. 93, Thai Hung Urban Area (Package 05 My Gia Urban Area), Vinh Thai Commune, Nha Trang City, Khanh Hoa Province	Business Location
- Land plot No. 2158, map sheet No. 1, street No. 3, Residential Lot No. 11B, Nam Can Tho urban area, Phu Thu ward, Cai Rang district, Can Tho city	Business Location
- Land Lot No. 2263, 2264, Map No. 19, Tan Loi Ward, Buon Ma Thuot City, Dak Lak Province	Business Location
- 1st, 2nd, 3rd floors of Vinh Quang Group Building, Lot DX, Southwest urban area of Linh Dam Lake, Thinh Liet Ward, Hoang Mai District, Hanoi City	Transaction offices, warehouses

b) Foreign currencies

	31/12/2024	01/01/2024
- USD	30,618.67	17,973.41

23. TOTAL REVENUE FROM SALES OF GOODS AND RENDERING OF SERVICES

	Year 2024	Year 2023
	VND	VND
Revenue from sale of goods	1,295,335,819,163	1,113,923,395,862
Revenue from rendering of services	414,291,049	1,652,894,444
	<u>1,295,750,110,212</u>	<u>1,115,576,290,306</u>
In which: Revenue from related parties (Detailed in Note No.37)	<u>78,957,964,381</u>	<u>82,383,193,719</u>

24. REVENUE DEDUCTIONS

	Year 2024	Year 2023
	VND	VND
Trade discount	66,201,457	843,812
Sale return	2,431,618,420	116,040,400
Sale discounts	-	1,974,206,775
	2,497,819,877	2,091,090,987
In which: Revenue from related parties (Detailed in Note No.37)	45,847,584	-

25. COSTS OF GOODS SOLD AND SERVICES RENDERED

	Year 2024	Year 2023
	VND	VND
Cost of goods sold	612,754,034,337	500,624,612,467
Provision for devaluation of inventories	(245,731,189)	1,015,703,941
	612,508,303,148	501,640,316,408
In which: Cost of goods sold to related parties (Detailed in Note No.37)	16,110,239,471	14,074,874,291

26. FINANCIAL INCOME

	Year 2024	Year 2023
	VND	VND
Interest income	1,521,884,737	320,229,027
Gain on exchange difference in the year	1,645,835,224	853,202,565
Gain on exchange difference AR the year - end	-	24,337,554
	3,167,719,961	1,197,769,146

27. FINANCIAL EXPENSES

	Year 2024	Year 2023
	VND	VND
Interest expenses	5,813,362,358	8,981,360,213
Loss on exchange rate differences incurred in the year	1,953,408,581	1,120,562,929
	7,766,770,939	10,101,923,142
In which: Financial expenses from related parties (Detailed in Note No.37)	-	1,008,594,118

28. SELLING EXPENSES

	Year 2024	Year 2023
	VND	VND
Raw materials	5,202,221,559	4,901,299,665
Labour expenses	239,310,925,942	222,031,978,075
Depreciation expenses	4,247,869,913	3,667,267,019
Promotion and sponsorship expenses	6,959,455,962	2,194,660,333
Expenses of outsourcing services	94,854,597,003	85,997,804,747
Other expenses in cash	23,872,792,022	12,312,202,924
	374,447,862,401	331,105,212,763
In which: Selling expenses purchased from related parties (Detailed in Note No.37)	1,855,183,799	1,522,345,320

29. GENERAL AND ADMINISTRATIVE EXPENSES

	Year 2024	Year 2023
	VND	VND
Raw materials	2,975,642,201	2,611,604,107
Labour expenses	13,180,952,060	16,131,521,551
Depreciation expenses	2,482,196,399	2,525,278,308
Provision expenses/ Reversal of provision expenses	(318,298,718)	133,893,505
Appropriation for establishment of the science and technology development fund	-	3,000,000,000
Tax, Charge, Fee	1,632,090,295	1,319,730,129
Expenses of outsourcing services	12,573,516,097	9,937,429,397
Other expenses in cash	5,118,786,149	3,407,790,030
	37,644,884,483	39,067,247,027

30. OTHER EXPENSES

	Year 2024	Year 2023
	VND	VND
Fines	410,011,434	1,493,305,888
Depreciation expenses are not deductible	135,408,120	135,408,120
Others	42,129,298	169,220,451
	587,548,852	1,797,934,459

31. CURRENT CORPORATE INCOME TAX EXPENSES

	Year 2024 VND	Year 2023 VND
Income subject to CIT:		
Total profit before tax	263,999,037,890	231,338,130,575
Increase	665,466,556	1,846,000,982
- <i>Ineligible expenses</i>	665,466,556	1,846,000,982
Decrease	(109,714,718)	(270,739,718)
- <i>Interest on revaluation of foreign currencies at the end of the year</i>	(109,714,718)	(270,739,718)
CIT taxable income	264,554,789,728	232,913,391,839
Taxable income from preferential activities	261,605,224,442	214,309,187,070
Taxable income from non-preferential activities	2,949,565,286	18,604,204,769
CIT expenses		
Current CIT expenses of preferential activities	52,321,044,888	21,430,918,707
Current CIT expenses of non-preferential activities	589,913,058	3,720,840,954
CIT is reduced	(26,160,522,444)	(10,715,459,354)
CIT adjustments of previous years to current corporate income tax expenses this year	16,442,807	5,613,968
Current CIT expenses	26,766,878,309	14,441,914,275
Tax payable at the beginning of period	2,576,300,307	976,305,142
Tax paid in the period	(13,894,743,114)	(12,841,919,110)
CIT payable at the end of the year	15,448,435,502	2,576,300,307

32. BASIC EARNINGS PER SHARE

Basic earnings per share distributed to common shareholders of the Company are calculated as follows:

	Year 2024 VND	Year 2023 VND
Net profit after tax	237,232,159,581	216,896,216,300
Adjustment	(25,333,511,768)	(29,117,530,401)
- <i>Temporary deduction of the Welfare Reward Fund, Executive Board Bonus (*)</i>	(25,333,511,768)	(29,117,530,401)
Profit distributed to common shares	211,898,647,813	187,778,685,899
Average number of outstanding common shares in circulation in the year	16,229,042	16,229,042
Basic earnings per share	13,057	11,571

(*) The amount of temporary deduction of the 2024 Welfare Reward Fund and Executive Board Bonus are temporarily calculated by the rate of deduction from the Welfare Reward Fund according to the rate of deduction of funds approved in the Resolution of the 2024 Annual General Meeting of Shareholders No. 146/2024/NQ-DHDCD dated 05/04/2024.

As at 31 December 2024, the Company does not have shares with dilutive potential for earnings per share.

33. BUSINESS AND PRODUCTIONS COST BY ITEMS

	Year 2024	Year 2023
	VND	VND
Raw materials	332,549,052,810	308,064,710,212
Labour expenses	336,941,039,911	315,748,482,462
Depreciation expenses	69,205,646,092	59,703,409,734
Expenses of outsourcing services	122,374,316,039	111,514,549,353
Other expenses in cash	49,224,901,457	27,566,782,983
	<u><u>910,294,956,309</u></u>	<u><u>822,597,934,744</u></u>

34. FINANCIAL INSTRUMENTS

Financial risk management

The Company's financial risks include market risk, credit risk and liquidity risk. The Company has developed its control system to ensure the reasonable balance between cost of incurred risks and cost of risk management. the Board of Management of the Company is responsible for monitoring the risk management process to ensure the appropriate balance between risk and risk control.

Market risk

The Company's business operations will bear the risks of changes in exchange rates and interest rates.

Exchange rate risk

The Company bears the risk of interest rates due to the transaction made in a foreign currency other than VND such as: borrowings and debts, revenue, cost, importing materials, good, machinery and equipment.

Interest rate risk

The Company bears the risk of interest rates due to the fluctuation in fair value of future cash flow of a financial instrument in line with changes in market interest rates if the Company has time or demand deposits, borrowings and debts subject to floating interest rates. The Company manages interest rate risk by analyzing the market competition situation to obtain interest beneficial for its operation purpose.

Credit Risk

Credit risk is the risk of financial loss to the Company if a counterparty fails to perform its contractual obligations. The Company has credit risk from operating activities (mainly to trade receivables) and financial activities (including deposits, loans and other financial instruments), detailed as follows:

Hanoi CPC1 Pharmaceutical Joint Stock CompanyHa Binh Phuong Industrial Cluster, Van Binh
Commune, Thuong Tin District, Hanoi**Financial Statements**

For the fiscal year ended as at 31 December 2024

	Under 1 year VND	From 1 to 5 years VND	Over 5 years VND	Total VND
As at 31/12/2024				
Cash and cash equivalents	39,027,489,445	-	-	39,027,489,445
Trade and other receivables	297,406,733,959	3,576,969,012	-	300,983,702,971
Loans	5,000,000,000	-	-	5,000,000,000
	341,434,223,404	3,576,969,012	-	345,011,192,416
As at 01/01/2024				
Cash and cash equivalents	79,068,551,382	-	-	79,068,551,382
Trade and other receivables	221,068,631,368	3,005,883,684	-	224,074,515,052
	300,137,182,750	3,005,883,684	-	303,143,066,434

Liquidity Risk

Liquidity risk is the risk that the Company has trouble in settlement of its due date financial obligations due to the lack of funds. Liquidity risk of the Company mainly arises from different maturity of its financial assets and liabilities.

Due date for payment of financial liabilities based on expected payment under the contracts (based on cash flow of the original debts) as follows:

	Under 1 year VND	From 1 to 5 years VND	Over 5 years VND	Total VND
As at 31/12/2024				
Borrowings and debts	41,694,687,517	30,450,000,000	-	72,144,687,517
Trade and other payables	91,238,538,362	131,500,000	-	91,370,038,362
Accrued expenses	1,013,834,994	-	-	1,013,834,994
	133,947,060,873	30,581,500,000	-	164,528,560,873
As at 01/01/2024				
Borrowings and debts	57,980,515,514	43,485,000,000	-	101,465,515,514
Trade and other payables	67,310,532,638	138,000,000	-	67,448,532,638
Accrued expenses	893,207,127	-	-	893,207,127
	126,184,255,279	43,623,000,000	-	169,807,255,279

The Company believes that risk level of loan repayment is controllable. The Company has the ability to pay due debts from cash flows from its operating activities and cash received from mature financial assets.

35. ADDITIONAL INFORMATION FOR THE ITEMS OF THE STATEMENT OF CASH FLOWS

	Year 2024 VND	Year 2023 VND
a) Proceeds from borrowings during the year		
Proceeds from ordinary contracts	103,489,697,885	120,681,666,391
b) Actual repayments on principal during the year		
Repayment on principal from ordinary contracts	133,397,027,719	169,197,863,909

36. SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

There have been no significant events occurring after the reporting period, which would require adjustments or disclosures to be made in the Financial Statements.

37. TRANSACTION AND BALANCES WITH RELATED PARTIES

List and relation between related parties and the Company are as follows:

Related parties	Relation
Ms. Le Thi Kim Anh	Major shareholder and related person of the Key Management Member
Mr. Nguyen Tien Lung	Major shareholder and related person of the Key Management Member
Ms. Phung Thanh Huong	Major shareholder and related person of the Key Management Member
Medzavy Pharmaceutical Joint Stock Company	Mr. Le Nam Thang is the Chairman of the Board of Directors of the Company and the Director and Legal Representative of this Company
CPC1 Central Pharmaceutical Joint Stock Company	Mr. Nguyen Doan Liem is a Member of the Board of Directors of the Company and a Member of the Board of Directors of this Company
Tan Thinh Pharmaceutical Co., Ltd.	Mr. Nguyen Thanh Binh is a Member of the Board of Directors of the Company and is the Director and Legal Representative of this Company
VNP Pharmaceutical Co., Ltd.	Mr. Nguyen Thanh Binh is a Member of the Board of Directors of the Company and Deputy Director of this Company
UPHARMA Joint Stock Company	Mr. Le Nam Thang is the Chairman of the Board of Directors of the Company and the Chairman of the Board of Directors and the Legal Representative of this Company Mr. Nguyen Thanh Binh is a Member of the Board of Directors of the Company and a Member of the Board of Directors of this Company
UPHARMA Solutions and Technology Co., Ltd. The members of the Board of Directors, the Board of Management, the Board of Supervision/ Audit Committee	Mr. Nguyen Thanh Binh is the Director of this company Key management personnel

In addition to the information with related parties presented in the above Notes. During the year, the Company has transactions with related parties as follows:

Hanoi CPC1 Pharmaceutical Joint Stock Company

Ha Binh Phuong Industrial Cluster, Van Binh
Commune, Thuong Tin District, Hanoi

Financial Statements

For the fiscal year ended as at 31 December 2024

	Year 2024	Year 2023
	VND	VND
Revenue from sales and services	78,957,964,381	82,383,193,719
- CPC1 Central Pharmaceutical Joint Stock Company	13,452,381	1,051,223,333
- Tan Thinh Pharmaceutical Co., Ltd.	39,102,963,728	42,187,400,115
- VNP Pharmaceutical Co., Ltd.	34,559,650,838	36,025,733,451
- UPHARMA Joint Stock Company	5,272,596,814	3,118,836,820
- Medzavy Pharmaceutical Joint Stock Company	9,300,620	-
Returned sales	45,847,584	-
- VNP Pharmaceutical Co., Ltd.	45,847,584	-
Purchase of goods and services	18,744,253,841	16,247,219,611
In which	18,744,253,841	16,247,219,611
<i>Purchase for production and purchase of goods</i>	<i>16,110,239,471</i>	<i>14,074,874,291</i>
<i>Cost of sales</i>	<i>1,855,183,799</i>	<i>1,522,345,320</i>
<i>Upfront costs</i>	<i>778,830,571</i>	<i>650,000,000</i>
- CPC1 Central Pharmaceutical Joint Stock Company	2,523,614,370	2,172,345,320
- Tan Thinh Pharmaceutical Co., Ltd.	15,984,677,172	13,464,083,920
- VNP Pharmaceutical Co., Ltd.	-	190,713,571
- UPHARMA Joint Stock Company	125,562,299	420,076,800
- Ms. Phung Thanh Huong	110,400,000	-
Loan interest	-	1,008,594,118
- Mr. Nguyen Thanh Binh	-	833,251,854
- Mr. Nguyen Doan Liem	-	1,643,636
- Mr. Le Nam Thang	-	173,698,628

Remuneration of key management persons:

	Position	Year 2024	Year 2023
		VND	VND
Mr. Le Nam Thang	Chairman of the Board of Directors, Deputy General Director	836,000,001	683,284,001
Mr. Nguyen Doan Liem	Member of the Board of Directors	56,000,000	51,000,000
Mr. Nguyen Thanh Binh	Member of the Board of Directors, General Director	2,425,784,402	3,039,231,662
Mr. Vu Van Ha	Member of the Board of Directors (Term 2020-2024 expires on 05/04/2024)	32,000,000	51,000,000
Mr. Tran Nghia Loi	Member of the Board of Directors (Appointed on 05/04/2024)	24,000,000	-
Mr. Tran Minh Thanh	Deputy General Director	533,795,001	412,184,001
Ms. Dang Thi Thu Thuy	Chief Accountant	442,571,183	309,189,912
Ms. Ta Thi Hai Huyen	Persons authorized to disclose information	382,383,333	255,544,000
Ms. Tran Thuy Khanh	Head of the Supervisory Board	272,000,000	271,284,000
Ms. Ha Thi Mai	Member of the Supervisory Board (Appointed on 05/04/2024)	233,495,405	-
Ms. Nguyen Thi Kim Oanh	Member of the Supervisory Board (Appointed on 05/04/2024)	502,377,994	-
Ms. Tran Thi Phuong Thao	Member of the Supervisory Board (Term 2020-2024 expires on 05/04/2024)	590,507,862	481,223,817
Ms. Truong Thi Hue	Member of the Supervisory Board (Term 2020-2024 expires on 05/04/2024)	12,000,000	18,500,000

In addition to the above related parties transactions, other related parties did not have any transactions during the year and have no balance at the end of the fiscal year with the Company.

38. COMPARATIVE FIGURES

The comparative data is the data on the Financial Statements for the fiscal year ended December 31, 2023 which has been audited by VACO Auditing Co., Ltd.



Nguyen Thi Xuan Hoan

Preparer

Hanoi, 29 March 2025



Dang Thi Thu Thuy

Chief Accountant



Le Nam Thang

Chairman of the Board of Directors

